



The original disclosure in Japanese was released on Oct. 25, 2022 at 15:30 (GMT+9)

To whom it may concern,

Company name: Takara Holdings Inc.
 Company representative: Mutsumi Kimura, President
 Securities code and stock exchange listings: 2531 Tokyo (Prime section)
 Inquiries: Masakazu Usami, General Manager of Financial & Investor Relations Dept.
 TEL: (075)241-5124

Revision of Consolidated Business Results Forecast for the First Half of the Fiscal Year Ending March 31, 2023

Kyoto, Japan—Takara Holdings announced revisions to the business results forecast for the first half of the fiscal year ending March 31, 2023 (from April 1, 2022, to March 31, 2023) that it released on August 4, 2022, as stated below. These revisions were based on consideration of recent performance trends.

1. Revised figures for the business results forecast for the first half of the fiscal year ending March 31, 2023 (from April 1, 2022, to September 30, 2022)

(Millions of yen / %)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (August 4, 2022, announcement)	159,000	16,700	17,200	9,100	46.03yen
Revised forecast (B)	164,279	19,614	19,972	10,873	55.00yen
Change (B—A)	5,279	2,914	2,772	1,773	—
Change (%)	3.3	17.4	16.1	19.5	—
Reference: Previous business results (First half of the fiscal year ended March 31, 2022)	141,213	21,616	21,884	10,050	50.84yen

2. Reason for revision

For the first half of the fiscal year ending March 31, 2023, net sales of Takara Shuzo and the Takara Shuzo International Group are expected to be roughly the same level as the previous forecast (announced on August 4, 2022). Meanwhile, net sales are expected to exceed the previous forecast for the Takara Bio Group, with the seventh wave of COVID-19 having driven the sales of relevant testing products to outperform the forecast.

In terms of profit, Takara Shuzo expects operating income to increase contrary to the previous forecast mainly due to decreases in costs, and the Takara Shuzo International Group expects operating income to be roughly in line with the forecast. The Takara Bio Group is expected to report an operating income higher than the forecast, due to an increase in gross profit following the increase in net sales.

As a result, operating income, ordinary income, and net income attributable to owners of the parent are expected to exceed the previous forecast for the Takara Group as a whole.

Further, today consolidated subsidiary Takara Bio Inc. (Tokyo Stock Exchange Prime Market, security code number: 4974) also announced revisions to forecasts for the six-month period ended September 30, 2022.

3. Full-year business results forecast for the fiscal year ending March 31, 2023

The Company is currently evaluating whether or not revisions to forecasts for consolidated business results for the full fiscal year are necessary and considering the details of possible revisions. The Company will make an announcement in this regard when it announces its business results for the first half on November 10, 2023.

* The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the business result figures scheduled to be announced on November 10, 2022.

Cautionary Statement on the Use of This Document

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in

selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.